AstraZeneca To Break Ground In Russia As MNCs Build Stronger Base In The Country
This article was originally published in PharmAsia News
Executive Summary
Scheduled to break ground in April, AstraZeneca PLC's investment of more than $150 million into construction of a drug manufacturing plant in Russia indicates the U.K.-based firm's confidence and long-term commitment to the emerging Russian market